# Astellas and Kelonia Partner for In Vivo CAR T Cell Therapies
## Main Ideas:
– Chimeric antigen receptor (CAR) T cell therapy involves extracting, engineering, and reintroducing T cells to patients receiving chemotherapy.
– Issues with current processes include dosage, effectiveness, and cell manufacturability.
– Astellas and Kelonia have formed an $800 million partnership to develop in vivo CAR T cell therapies.
– In vivo approach eliminates the need to culture immune cells outside the body, potentially accelerating treatment and enhancing patient access to therapy.
### Author’s Take:
The collaboration between Astellas and Kelonia to work on in vivo CAR T cell therapies for cancer treatment aims to overcome existing challenges in dosage, effectiveness, and manufacturability of current CAR T cell processes. This partnership represents a significant step towards improving the accessibility and efficiency of CAR T cell therapy, potentially benefiting a larger number of patients in need of innovative treatment options.
Click here for the original article.